Journal articles: 'Jian shu(wu shu)'

1

WU, Peichen. "Traveling Japan, Writing Japan：The Translation and Publishing of the Travelogue Wareteki Nihon." Border Crossings: The Journal of Japanese-Language Literature Studies 13, no. 1 (December 30, 2021): 53–60. http://dx.doi.org/10.22628/bcjjl.2021.13.1.53.

Full text

Abstract:

The travelogue Wareteki Nihon was published in December 2018 by Hakushui Sha, and included the work of eighteen Taiwanese writers from various generations. All their works in the text relate to their travels in Japan. These Taiwanese writers are Kan Yao-Ming, Ko Yu-fen, Huang Li-Chun, Wang Sheng-Hong, Jiang E, Chen Bo-Chin, Hu Mu-Ching, Sheng Hao-We, Chu He-Chih, Wu Ming-Yi, Lu Hui-Hsin, Yi Ge-Yan, Yen Shu-Hsia, and Liu Shu-Hui, whose works in this anthology depict Japanese scenery, culture and literature, and so on. This paper will focus on how this publishing project started, the process of producing this travelogue, and the evaluations and responses of Japan’s literary circle and the mass media to it after its publication in Japan.

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Shang‐Jen. "Guihan Luo. Jin dai xi fang shi Hua sheng wu shi [History of Western Botanical and Zoological Studies in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 434 pp., illus., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥46 (paper)." Isis 99, no. 2 (June 2008): 380–81. http://dx.doi.org/10.1086/591325.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fang, Li-Zhi. "Jiang Xiaoyuan ;, Wu Yan . Zijin shan tian wen tai shi gao: Zhongguo tian wen xue xian dai hua ge an. [History of Purplemountain Observatory.] (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 219 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2004. 29 (paper)." Isis 99, no. 3 (September 2008): 645–46. http://dx.doi.org/10.1086/593267.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fan, Fa-ti. "Zonggang Hu. Jingsheng sheng wu diao cha suo shi gao [Historical manuscript of Fan Memorial Institute of Biology]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 250 pp., illus., figs., tables, bibl., index. Jinan: Shangdong jiao yu chu ban she [Shandong Education Press], 2005. 29 yuan (paper)." Isis 99, no. 1 (March 2008): 214. http://dx.doi.org/10.1086/589390.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, Xiaoyu, Jing Lin, Qing Wang, Siyao Xiao, and Ling Wang. "Prescription rules of Qingzhu Fu, Ziming Chen, and Qian Wu for threatened miscarriage based on traditional Chinese medicine inheritance auxiliary platform." Traditional Medicine and Modern Medicine 03, no. 03 (September 2020): 185–90. http://dx.doi.org/10.1142/s257590002050010x.

Full text

Abstract:

Background: To explore the prescription rules of famous ancient physicians in the treatment of threatened miscarriage. Methods: Traditional Chinese Medicine (TCM) prescriptions for threatened miscarriage were screened out of Fu Ren Da Quan Liang Fang by Ziming Chen, Yi Zong Jin Jian by Qian Wu, and Fu Qing Zhu Nv Ke by Qingzhu Fu. Data were standardized and analyzed through the TCM inheritance auxiliary platform. Results: A total of 29 prescriptions for threatened miscarriage were screened. Dang Gui, E Jiao, Gan Cao, Chuan Xiong, Bai Shao were the top five frequently prescribed Chinese herbs. The common herb–herb combinations used by Ziming Chen contained E Jiao, Dang Gui, Chuan Xiong, Ai Ye, Cong Bai, and Sang Ji Sheng. Ren Shen, Gan Cao, and Bai Zhu were the common herbal groups used by Qingzhu Fu. Huang Qi, Shu Di Huang, Bai Shao, Dang Gui, and Gan Cao were one of Qian Wu’s core prescriptions, with Dang Gui and Chuan Xiong being the others. According to the analysis of four Qi, five flavors, and meridian tropism of the prescriptions, herbs with the warm nature, or with the sweet, pungent, bitter flavors topped the list of application. The top six meridian tropisms of high-frequency herbs were: liver, spleen, lung, kidney, heart, and stomach meridian. Conclusion: Based on the principle of restoring the balance within the organs and enriching Qi and blood, clinical treatment of threatened miscarriage involves invigorating the Chong and Ren channels, nourishing Yin, dispelling cold and wind, generating and activating blood, regulating and harmonizing Qi.

APA, Harvard, Vancouver, ISO, and other styles

6

Chung, Juliette Yuehtsen. "Bo Liang. Ji shu yu di guo yi yan jiu: riben zai Zhongguo de zhi min ke yan ji gou [Researches on Technology and Imperialism: Japanese Colonial Scientific Research Institutes in China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 345 pp., figs., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. ¥38 (paper).Jianping Han;, Xingsui Cao;, Liwei Wu. Ri wei shi qi de zhi min di ke yan ji gou: li shi yu wen xian [Colonial Scientific Institutions during the Japanese Occupation and Puppet Manchukuo Period: History and Literature]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 468 pp., figs., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2006. ¥49 (paper)." Isis 99, no. 2 (June 2008): 429–30. http://dx.doi.org/10.1086/591369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tseng, Chu-Yao, Ching-Wen Huang, Hsin-Chia Huang, and Wei-Chen Tseng. "Utilization Pattern of Traditional Chinese Medicine among Fracture Patients: A Taiwan Hospital-Based Cross-Sectional Study." Evidence-Based Complementary and Alternative Medicine 2018 (September 30, 2018): 1–9. http://dx.doi.org/10.1155/2018/1706517.

Full text

Abstract:

Traditional Chinese medicine (TCM) divides fracture treatment into three stages. Many TCM herbs and formulas have been used to treat fractures for thousands of years. However, research regarding the Chinese herbal products (CHPs) that should be used at different periods of treatment is still lacking. This study aims to identify the CHPs that should be used at different periods of treatment as well as confirm the TCM theory of fracture periods medicine. We used prescriptions of TCM outpatients with fracture diagnoses analyzed using the Chang Gung Research Database (CGRD) from 2000 to 2015. According to the number of days between the date of the fracture and the clinic visit date, all patients were assigned to one of three groups. Patients with a date gap of 0-13 days were assigned to the early period group; those with a date gap of 14-82 days were assigned to the middle period group; and those with a date gap of 83-182 days were assigned to the late period group. We observed the average number of herbal formulas prescribed by the TCM doctor at each visit was 2.78, and the average number of single herbs prescribed was 6.47. The top three prescriptions in the early fracture period were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Wu-ling-san. In the middle fracture period, the top three formulas were Zheng-gu-zi-jin-dang, Shu-jing-huo-xue-tang, and Zhi-bai-di-huang-wan. In the late fracture period, the top three formulas were Shu-jing-huo-xue-tang, Gui-lu-er-xian-jiao, and Du-huo-ji-sheng-tang. The main single herbs used in the early fracture period were Yan-hu-suo, Gu-sui-bu, and Dan-shen. From the middle to the late period, the most prescribed single herbs were Xu-duan, Gu-sui-bu, and Yan-hu-suo. We concluded that the results showed that the CGRD utilization pattern roughly meets the TCM theory at different fracture periods.

APA, Harvard, Vancouver, ISO, and other styles

8

Xu, Ling. "Comment on “Weak tensile characteristics of loess in China — An important reason for ground fissures” by Ping Sun, Jian-bing Peng, Li-wei Chen, Yue-ping Yin, Shu-ren Wu [Engineering Geology 108 (2009) 153–159]." Engineering Geology 114, no. 1-2 (June 2010): 105–6. http://dx.doi.org/10.1016/j.enggeo.2010.04.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Sun, Ping. "Reply to the discussion by Ling Xu on “Weak tensile characteristics of loess in China — An important reason for ground fissure” by Ping Sun, Jian-Bing Peng, Li-Wei Chen, Yue-Ping Yin and Shu-Ren Wu, [Engineering Geology 108 (2009) 153–159]." Engineering Geology 114, no. 1-2 (June 2010): 107. http://dx.doi.org/10.1016/j.enggeo.2010.04.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

김혜정. "A Study on the Bearing Ideas in Qin Han Jian Ri Shu - Focused on Zhou Jia Tai and Shui Hu Di Qin Jian Ri Shu and Kong Jia Po Han Jian Ri Shu." Journal of Study on Language and Culture of Korea and China ll, no. 33 (October 2013): 609–38. http://dx.doi.org/10.16874/jslckc.2013..33.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lu, Shun, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, et al. "Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT034. http://dx.doi.org/10.1158/1538-7445.am2022-ct034.

Full text

Abstract:

Abstract Background: METex14 mutations was reported in 3~4% of NSCLC patients and became a new target in the treatment of NSCLC. SCC244 is a highly selective and potent oral MET inhibitor. This is the first report of data from an ongoing single-arm phase II study of SCC244 in NSCLC patients with METex14 mutations (GLORY study). Methods: GLORY study is an open label, international, multi-center, single-arm phase II study to evaluate the efficacy and safety of SCC244 in patients with locally advanced or metastatic NSCLC harboring METex14 mutations which was confirmed by central laboratory. The enrolled patients have either failed one or two prior lines of systemic therapies or been not eligible/refused chemotherapy after being well-informed. SCC244 was taken orally at a dose of 300 mg once daily in 21-day treatment cycles until disease progression or intolerable toxicity. Tumor was evaluated every 6 weeks for the first 8 treatment cycles and every 9 weeks thereafter. The primary endpoint was objective response rate (ORR) assessed by blinded independent review committee (BIRC) per RECIST 1.1, secondary endpoints include ORR by investigator assessment (INV), duration of response (DoR), time to response (TTR) and safety etc. Post-hoc analysis was done to explore the intracranial anti-tumor activity. Results: At data cut-off on May 6th, 2021, a total 73 patients screened from 163 patients in 42 sites were treated at 300 mg QD dose and had ≥2 post-baseline tumor assessments or discontinued for any reason. 69 of them were with METex14 mutation confirmed by central laboratory. In the 69 patients, ORR by BIRC was 60.9% (95% CI: 48.4%, 72.4%) overall, 66.7% (95% CI: 50.5, 80.4) and 51.9% (95% CI: 31.9, 71.3) in treatment naïve and previously treated patients respectively. Median DoR was 8.2 months (95% CI: 4.8, NE) and median PFS was 7.6 months (95% CI: 4.2, NE), tumor response from 30 of 42 responders was still ongoing. The response occurred fast with a median TTR of 1.4 months (range: 1.2, 4.2). Partial response was observed in 8 of 10 patients with brain metastasis. 5 patients who had brain metastasis selected as targeted lesion had intracranial response by INV with a median intracranial tumor shrinkage of 57% (range: 34%, 71%). The most common (≥20%) treatment-related adverse events (TRAEs) of any grade were peripheral edema, headache, nausea, loss of appetite, hypoalbuminemia, ALT increase and vomiting. The incidence of ≥ grade 3 TRAEs was 43.8%. TRAEs leading to treatment discontinuation occurred in 6.8% patients, among which peripheral edema was the most common (4.1%). Conclusions: The data shows high and robust efficacy of SCC244 in NSCLC patients with METex14 mutations across treatment lines and encouraging intracranial anti-tumor activity. The safety profile was favorable with manageable toxicity. The data supports SCC244 as a valuable targeted treatment option for METex14 NSCLC patients. Citation Format: Shun Lu, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, Tanaka Kentaro, Lin Wu, Xuhong Min, Wei Zhang, Dingzhi Huang, Yongqian Shu, Chengzhi Zhou, Min Li, Xiaorong Dong, Chong Bai, Lu Li, Jiuwei Cui, Li Zhang, Lejie Cao, Xiaoling Li, AiMin Zang, Haruki Kobayashi, Yiping Zhang, Yan Yu, Xiuwen Wang, Terufumi Kato, Shoichiro Yamamoto, Yuki Shinno, Xiaoyan Lin, Yanqiu Zhao, Yanping Hu, Qitao Yu, Ziping Wang, Masahiro Kodani, Jian Fang, Jialei Wang, Meiqi Shi, Diansheng Zhong, Wen Dong, Hiroshi Tanaka, Yasuto Yoneshima, Minghui Sun, Jun Zhou, Qiuxia Wu, Meng Li. Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT034.

APA, Harvard, Vancouver, ISO, and other styles

12

Pankenier, David W. "The Bamboo Annals revisited: problems of method in using the Chronicle as a source for the chronology of Early Zhou. Part 2: The congruent mandate chronology in Yi Zhou shu." Bulletin of the School of Oriental and African Studies 55, no. 3 (October 1992): 498–510. http://dx.doi.org/10.1017/s0041977x00003670.

Full text

Abstract:

The account given of the Bamboo Annals pre-Conquest chronology in Part 1 of this paper bears comparison with the internally consistent chronological sequence found in Yi Zhou shu, whose coherence has not been fully appreciated by those attempting to reconstruct the chronology. As we saw in the discussion of King Wu's reign in Part 1, Yi Zhou shu ‘Da kuang’ and ‘Wen zheng’ chapters are correct in dating the appointment of King Wu' s siblings as viceroys in the former Shang domain, which event we know took place in the Conquest year, to the 13th year of the Mandate, a finding that is fundamentally incompatible with Chou Fa-kao's, David Nivison' s, and Edward Shaughnessy' s account. The same two chapters in combination with ‘Zuo luo’ are also correct in implying that King Wu died in the 14th year. Furthermore, ‘Wen zhuan’ chapter of Yi Zhou shu correctly dates King Wen' s demise to the ‘9th year of the Mandate’ in those very words.

APA, Harvard, Vancouver, ISO, and other styles

13

Kang, Y.-S., and K.-D. Park. "BIOMECHANICAL ANALYSIS OF WU-SHU 540° WHIRLWIND KICK." Journal of Biomechanics 40 (January 2007): S613. http://dx.doi.org/10.1016/s0021-9290(07)70601-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Wu, Jiong, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, et al. "Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study." Cancer Research 82, no. 4_Supplement (February 15, 2022): PD8–08—PD8–08. http://dx.doi.org/10.1158/1538-7445.sabcs21-pd8-08.

Full text

Abstract:

Abstract Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine have shown clinically and statistically meaningful progression free survival and overall survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer in phase 3 study. We compared the efficacy and safety of adding pyrotinib to trastuzumab and docetaxel vs placebo, trastuzumab and docetaxel as neoadjuvant treatment in women with HER2-positive early or locally advanced breast cancer (ABC) in this randomized, double-blind, multicenter, phase 3 study. Methods: Treatment naive patients with HER2-positive early or locally ABC (T2-3, N0-3, M0) were randomly assigned (1:1) to pyrotinib arm receiving 4 neoadjuvant cycles of pyrotinib (400 mg po qd, d1-21, q3w), trastuzumab (8 mg/kg iv, cycle 1 d1, then 6 mg/kg d1 q3w) and placebo arm with docetaxel (100 mg/m2 iv d1, q3w) or placebo, trastuzumab and docetaxel. Randomization was done via a centralized interactive web-response system and stratified by primary tumor size (>2 cm and ≤5cm, or >5cm) and hormone receptor status (ER positive and/or PR positive, or negative for both). After surgery, patients received 3 cycles of intravenous fluorouracil, epirubicin, and cyclophosphamide followed by anti-cancer treatment (anti-HER2 therapy, radiotherapy, or endocrine therapy) at physicians’ discretion in accordance with clinical practice guidelines. The primary endpoint was total pCR rate (tpCR; defined as absence of any residual invasive cancer in the breast and lymph nodes [ypT0/is, ypN0]), assessed by an independent review committee (IRC). This study is registered with ClinicalTrials.gov, number NCT03588091. The data cutoff date was April 30, 2021. Results: Between July 23, 2018 and January 8, 2021, a total of 355 patients were randomized (pyrotinib arm, n=178; and placebo arm, n=177; mean [SD] age, 48.8 [9.4] years). Baseline demographics and disease characteristics were well balanced. In the full analysis set, IRC-assessed tpCR rates were 41.0% (73 of 178) in the pyrotinib arm and 22.0% (39 of 177) in the placebo arm (difference, 19.0% [95% CI, 9.5%-28.4%]; one-sided P<0.0001). The local pathologist-assessed tpCR rates were 44.4% (79 of 178) and 24.3% (43 of 177) in the pyrotinib arm and the placebo arm, respectively. Incidence of grade ≥3 adverse events (AEs) was 71.3% (127 of 178) in the pyrotinib arm and 37.3% (66 of 177) in the placebo arm. Of the most-common grade ≥3 AEs (≥5% of patients in either arm), the incidences of diarrhea (79 of 178 [44.4%] vs 9 of 177 [5.1%]), decreased WBC count (29 of 178 [16.3%] vs 24 of 177 [13.6%]), vomiting (23 of 178 [12.9%] vs 2 of 177 [1.1%]), anemia (11 of 178 [6.2%] vs 2 of 177 [1.1%]), and hypokalemia (9 of 178 [5.1%] vs 0) were higher in the pyrotinib arm compared with the placebo arm. Grade 3 diarrhea occurred mainly during the first treatment cycle and decreased in the second cycle and thereafter. No grade 4 or 5 diarrheas occurred. The median duration per grade 3 episode was 2.0 days and median cumulative duration of grade 3 episodes was 4.0 days. Only 1 patient (1 of 178 [0.6%]) in the pyrotinb arm experienced diarrhea-related discontinuation. Serious AEs were reported in 14.6% of patients (26 of 178) in the pyrotinib arm and 6.8% of patients (12 of 177) in the placebo arm. Conclusions: Pyrotinib, trastuzumab, and docetaxel as neoadjuvant treatment achieved a statistically significant and clinically meaningful improvement in IRC-assessed tpCR rate for patients with HER2-positive early or locally ABC compared with placebo, trastuzumab, and docetaxel, with an acceptable and manageable safety profile. These findings support pyrotinib, trastuzumab, and docetaxel as a new neoadjuvant treatment option in this patient population. Citation Format: Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Tao Zhang, Jianjun Zou. Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD8-08.

APA, Harvard, Vancouver, ISO, and other styles

15

Nagai, Masashi. "A Study of P. 3777, Wu-xin wèn-shu." JOURNAL OF INDIAN AND BUDDHIST STUDIES (INDOGAKU BUKKYOGAKU KENKYU) 36, no. 1 (1987): 111–18. http://dx.doi.org/10.4259/ibk.36.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Chen, Tien Li, and Pei Fen Hong. "Study on the Visual Image of Armchairs Furniture in Yangming Shu Wu." Advanced Materials Research 168-170 (December 2010): 2371–75. http://dx.doi.org/10.4028/www.scientific.net/amr.168-170.2371.

Full text

Abstract:

Yangming Shu Wu was originally named “Chung Hsing Hotel”. It was established in 1970 and opened since 1971.It is the only official residence chosen by late President Kai-Shek Chiang to be established in Taiwan. At present, Yangming Shu Wu is a importance in culture and history. This study investigated the visual image of armchairs in Yangming Shu Wu. Using SD questionnaire survey and statistical analysis were employed to conduct this study, and a total of 115 questionnaires were distributed. The result indicated that, the styles of armchairs could be divided into three categories: (1) Chinese style armchairs: most of them are Qing-style armchairs, which are characterized by the presence of leg rests and the sculptures of glossy ganoderma, symbol for good luck, or faces of animals, etc. at the end of chair legs. In terms of materials, teakwood, rosewood, and kingwood are the common materials. The most frequently used material is teakwood, which exhibits the image of rigidity, magnificence, classicality and nobility. (2) Western style armchairs: they are the typical Queen Anne style armchairs. In terms of materials, only teakwood is used, which exhibits the overall image of magnificence, classicality, curving, nobility, modernization, innovation, and uniqueness. (3) Chinese-western integrated style armchairs: they are mainly made of teakwood as well. Most of them are designed with the Qing-style chair legs, and the seat back is decorated with seat back fabrics with lining, which exhibits the overall image of rigidity, magnificence, classicality, straightness, and nobility.

APA, Harvard, Vancouver, ISO, and other styles

17

Choi, Kwan Young, and Kwi Jong Kim. "Wu-Shu Practitioner`s Exercise Emotion and the Expectation of the Result of the Exercise Depend on the Expertise of the Wu-Shu Director." Journal of Sport and Leisure Studies 37 (August 31, 2009): 1621–30. http://dx.doi.org/10.51979/kssls.2009.08.37.1621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

LIN, JIAN-ZHEN, and ZHI-QIANG ZHANG. "Bdelloidea of China: a review of progress on systematics and biology, with a checklist of species." Zoosymposia 4, no. 1 (June 30, 2010): 42–50. http://dx.doi.org/10.11646/zoosymposia.4.1.3.

Full text

Abstract:

This paper reviews the research on the systematics and biology of the superfamily Bdelloidea in China, with an updated checklist of 48 species belonging to 16 genera in the family Cunaxidae and 26 species belonging to nine genera in the family Bdellidae. Important contributions to the Chinese fauna of the Bdellidae were made by Tseng Yi-Hsiung (Taiwan), Hong Mei (former with Fudan University in Shanghai) and Lin Jian-Zhen (and colleagues in Fujian Academy of Agricultural Sciences, Fuzhou), and those to the Cunaxidae by Tseng Yi-Hsiung, Li Long-Shu (and colleagues in Southwest University, Chongqing) and Lin Jian-Zhen (and colleagues). There have been relatively few studies on the biology and use in biological control of the Bdelloidea in China, and these are briefly reviewed.

APA, Harvard, Vancouver, ISO, and other styles

19

Wu, J., C. Shu, and N. Zhao. "Simulation of Thermal Flow Problems via a Hybrid Immersed Boundary-Lattice Boltzmann Method." Journal of Applied Mathematics 2012 (2012): 1–11. http://dx.doi.org/10.1155/2012/161484.

Full text

Abstract:

A hybrid immersed boundary-lattice Boltzmann method (IB-LBM) is presented in this work to simulate the thermal flow problems. In current approach, the flow field is resolved by using our recently developed boundary condition-enforced IB-LBM (Wu and Shu, (2009)). The nonslip boundary condition on the solid boundary is enforced in simulation. At the same time, to capture the temperature development, the conventional energy equation is resolved. To model the effect of immersed boundary on temperature field, the heat source term is introduced. Different from previous studies, the heat source term is set as unknown rather than predetermined. Inspired by the idea in (Wu and Shu, (2009)), the unknown is calculated in such a way that the temperature at the boundary interpolated from the corrected temperature field accurately satisfies the thermal boundary condition. In addition, based on the resolved temperature correction, an efficient way to compute the local and average Nusselt numbers is also proposed in this work. As compared with traditional implementation, no approximation for temperature gradients is required. To validate the present method, the numerical simulations of forced convection are carried out. The obtained results show good agreement with data in the literature.

APA, Harvard, Vancouver, ISO, and other styles

20

Chien, Po-Chen, Rong-Hsuan Wang, Pin-Ru Chen, Yue-Ting Chen, Yi-Chang Chen, Yu-Hsin Chu, Chia-Chen Chien, et al. "Abstract 437: Hydrogen sulfide switches the glucose metabolism through sulfhydration on pyruvate kinase M2." Cancer Research 84, no. 6_Supplement (March 22, 2024): 437. http://dx.doi.org/10.1158/1538-7445.am2024-437.

Full text

Abstract:

Abstract Cancer cells reprogram their glucose metabolism from oxidative phosphorylation to aerobic glycolysis. This metabolic transformation is partly based on the activity alterations of a rate limiting enzyme known as the pyruvate kinase M2 (PKM2), which is responsible for the conversion of phosphoenolpyruvate (PEP) into pyruvate. Attributed to its critical regulatory role. PKM2 is recognized as the pivotal enzyme in cancer glucose metabolism By reducing the enzyme activity of PKM2, cancer cells attain a greater fraction of glycolytic metabolites for macromolecule synthesis needed for rapid proliferation. Hydrogen sulfide (H2S), an endogenously produced gasotransmitter that acts as a critical mediator in multiple physiological processes, modifies proteins mainly through the persulfide (-SSH) bond formation, which is called sulfhydration. Our preliminary study demonstrates that H2S stimulates PKM2 sulfhydration at multiple cysteine residues, including cysteine 326, leading to the destabilization of active tetrameric PKM2 form into dimers or monomers. The PKM2 dimer/monomer further translocates into the nucleus to simulate the activation of glycolytic related genes. Blocking PKM2 sulfhydration at cysteine 326 through amino acid mutation stabilizes PKM2 tetramer and crystal structure further indicates that the tetramer organization of PKM2C326S is different from the currently known T or R states, revealing PKM2C326S as a newly identified intermediate form. Blocking PKM2 sulfhydration at cysteine 326 inhibited cell proliferation and tumor growth in xenograft mouse model. In summary, our current study illustrates that H2S-mediated sulfhydration induces the dissociation of the PKM2 tetramer, resulting in the reduced PKM2 activity and subsequently inhibits breast cancer cell proliferation and tumor growth. Targeting the sulfhydration site of PKM2 emerges as a promising therapeutic target specific for cancer metabolism. Citation Format: Po-Chen Chien, Rong-Hsuan Wang, Pin-Ru Chen, Yue-Ting Chen, Yi-Chang Chen, Yu-Hsin Chu, Chia-Chen Chien, Shao-Yun Lo, Zhong-Liang Wang, Min-Chen Tsou, Ssu-Yu Chen, Guang-Shen Chiu, Wen-Ling Chen, Yi-Hsuan Wu, Hui-Ching Wang, Shu-Yi Lin, Wen-Ching Wang, Hsing-Jien Kung, Lu-Hai Wang, Hui-Chun Cheng, Kai-Ti Lin. Hydrogen sulfide switches the glucose metabolism through sulfhydration on pyruvate kinase M2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 437.

APA, Harvard, Vancouver, ISO, and other styles

21

Yue, Wu. "Analysis report on the spatial planning of streets and lanes of Shu Han Street Community." SHS Web of Conferences 169 (2023): 01007. http://dx.doi.org/10.1051/shsconf/202316901007.

Full text

Abstract:

Shu Han Street Community of Jiangxi Street is located in the centre of Wuhou District, Chengdu Province and there are many Tibetan resident agencies in this community. It is also close to Southwest Minzu University, People’s Government of Wuhou District, Customs Office, and Temple of Marquis Wu. Shu Han Street Community is richly populated by multiple ethnic groups and other social groups. As a community with a dense flow of people and complex population composition, the spatial planning structure of streets and lanes in residents’ lives should be analyzed in great detail. Through measured survey and questionnaire survey, we have collected objective information such as street structure and planning and subjective information such as residents’ wishes and expectations. After integrating the information obtained, we used professional knowledge of architecture, ekistics and other subjects to propose an optimization plan for three parts—streets, corners, and micro-landscapes.

APA, Harvard, Vancouver, ISO, and other styles

22

Chao, Xue-lin, Shu-zhen Jiang, Jian-wen Xiong, Jin-qiong Zhan, Bo Wei, Chun-nuan Chen, and Yuan-jian Yang. "Erratum to: Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics." Current Medical Science 40, no. 5 (October 2020): 997. http://dx.doi.org/10.1007/s11596-020-2256-3.

Full text

Abstract:

The article “Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics”, written by Xue-lin CHAO, Shu-zhen JIANG, Jian-wen XIONG, Jin-qiong ZHAN, Bo WEI, Chun-nuan CHEN, Yuan-jian YANG was originally published electronically on the publisher’s internet portal on June 2020 without open access. With the author(s)’ decision to opt for Open Choice, the copyright of the article is changed to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

APA, Harvard, Vancouver, ISO, and other styles

23

Liu, Yen-Lin, Yin-Ju Chen, Shu-Huey Chen, Yu-Mei Liao, Wu Shih-Pei, Yi-Hsuan Chen, Wan-Ling Ho, et al. "Abstract 6723: Application of in vitro drug screening of circulating tumor cells in pediatric glioma therapy." Cancer Research 83, no. 7_Supplement (April 4, 2023): 6723. http://dx.doi.org/10.1158/1538-7445.am2023-6723.

Full text

Abstract:

Abstract Twenty-one gliomas in patients aged 0-21 years were evaluated for drug sensitivity by ex vivo expanded circulating tumor cells (CTC). The results were correlated with clinical outcomes. Venous blood samples were obtained prior to drug treatment. Peripheral blood mononuclear cells were processed in a 3D cell culture system (EVA Select™, Cancer Free Biotech Ltd., Taipei, Taiwan) and cultured for 3 weeks. Expanded CTCs were successfully cultured into organoids from 18 out of 21 patients and were analyzed for ATP abundance. Staining with CD45, a marker for blood cells, and pancytokeratin, a marker for keratinocytes, was performed on the cultured cells. Staining of GFAP, a marker of glioma cells, was performed in a subset of samples. These cells were then tested in cytotoxicity assays in triplicate with a panel of chemotherapeutic and targeted agents at clinically relevant concentrations. The surviving fraction was normalized to a buffer-only control. Based on the percentage of cell viability, the agent was chosen for clinical treatment. Comparing the results among low-grade glioma (LGG; n = 6), diffuse midline glioma (DMG; n = 4), and high-grade glioma (HGG, n = 8; including glioblastoma multiforme [GBM; n = 5]), the mean surviving fraction to temozolomide was similarly high across the three tumor types (LGG vs. DMG vs. HGG = 57.5% vs. 50.6% vs. 49.5%, respectively). 6 of 6 patients in the LGG group showed CTC sensitivity to at least one chemotherapeutic agent tested. The clinical response of patients treated with selected agents was evaluated with the RANO criteria at 6 months after initiation of treatment. Among the 24 agents tested with clinical correlation, the CTC surviving fraction after exposure to the agent was significantly higher in patients who had progressive disease within 6 months (n = 11; 68%) vs. in patients with no progression at 6 months (n = 13; 39%; P = 0.039). Treating CTCs with histone deacetylase inhibitors in vitro resulted in a consistently lower surviving fraction (15.1% ± 12.0%) for DMG and HGG/GBM; however, clinical correlation was not available. The 1 patient with clinical correlation with HGG had a 34.9% surviving fraction to a Tyrosine kinase inhibitor (TKI) in vitro and showed a 42.9% shrinkage at 6 months after treatment with the TKI. The expansion of CTCs in patients with relapsed/refractory pediatric gliomas provides the ability to test drug sensitivity of patient-derived organoids. Our data suggest a correlation between the ex vivo drug sensitivity of CTCs and clinical response. Citation Format: Yen-Lin Liu, Yin-Ju Chen, Shu-Huey Chen, Yu-Mei Liao, Wu Shih-Pei, Yi-Hsuan Chen, Wan-Ling Ho, Liang-Yi Juo, Chia-Yau Chang, Jinn-Li Wang, Min-Yu Su, Pei-Chin Lin, Shih-Chung Wang, James S. Miser, Tai-Tong Wong, Yuan-Hung Wu, Peng Yuan Wang, Thierry Burnouf, Jeng-Fong Chiou, Long-Sheng Lu. Application of in vitro drug screening of circulating tumor cells in pediatric glioma therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6723.

APA, Harvard, Vancouver, ISO, and other styles

24

Yang, Benlong, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, et al. "Abstract P5-18-06: Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+ early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–18–06—P5–18–06. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-18-06.

Full text

Abstract:

Abstract Background: Diarrhea is a common side effect of many anti-cancer treatments, including chemotherapeutic agents, tyrosine kinase inhibitors, and pelvic radiotherapy. PHEDRA was a randomized, double-blind, multicenter, phase 3 study comparing the efficacy and safety of adding pyrotinib (an irreversible pan-ErbB inhibitor) to trastuzumab and docetaxel (pyrotinib arm) vs placebo, trastuzumab, and docetaxel (placebo arm) as neoadjuvant treatment in women with HER2+ early or locally advanced breast cancer (ClinicalTrials.gov: NCT03588091). We conducted this exploratory analysis to evaluate the effectiveness of proactive diarrhea management (PDM) according to the recommendation from independent data monitoring committee. Methods: Between July 23, 2018 and January 8, 2021, 355 patients were enrolled and randomized, of whom 212 and 143 patients were randomized before and after the implementation of PDM strategy. The diarrhea management strategy was strengthened with the early identification and proactive management of diarrhea, including use of loperamide as first choice of antidiarrheal agents and strict application of loperamide recommended dose (4 mg initially and an additional 2 mg following each diarrhea stool, not exceeding 16 mg/day). Primary prophylaxis with loperamide was not allowed. The incidence, severity, onset, and duration of diarrhea were summarized. The data cutoff date was April 30, 2021. Results: Of all 178 patients with pyrotinib arm, there were 43 (40.6%) and 56 (77.8%) patients applied loperamide as the first choice of antidiarrheal agents before and after the PDM implementation, respectively. The incidence of grade 3 diarrhea has decreased from 50.0% before the PDM implementation to 36.1% after the PDM implementation (Table 1). During neoadjuvant treatment period, grade 3 diarrhea mainly occurred during the first cycle of treatment for both treatment arms (C1: 20.8%), showing a sharp decreased trend during the following cycles (C2: 8.7%; C3: 5.4%; C4: 4.5%). Furthermore, among patients with pyrotinib arm, the incidences of grade 3 diarrhea in the first, second cycle and thereafter were lower in patients enrolled after the implementation of PDM than those enrolled before the PDM implementation (C1: 29.2%. vs 44.3%; C2: 10.1% vs 21.8%; C3: 7.2% vs 14.1%; C4: 4.5% vs 11.1%). Among patients with pyrotinib, compared with those enrolled before the PDM implementation, the median duration per diarrhea episode (4 days [IQR, 2-9] vs 2 days [1-5]), median duration per grade 3 diarrhea episode (2 days [IQR, 2-3] vs 2 days [1-2]), and median cumulative duration of grade 3 diarrhea (6 days [IQR, 3-9] vs 2 [2-5] days) were shortened in those enrolled after the PDM implementation. During neoadjuvant treatment period, 31 (17.4%) patients experienced diarrhea leading to pyrotinib dose reduction, and only 1 (0.6%) patient discontinued study treatment due to diarrhea in the pyrotinib arm. Conclusion: Pyrotinib tolerability was improved with PDM, which reduced the incidence and duration of grade 3 diarrhea. Grade 3 diarrhoea occurred mainly during the first cycle of treatment and reduced in the second cycle and thereafter. Diarrhea in the pyrotinib group was characterized by early onset and short duration and was generally manageable. Table 1.Characteristics of treatment-emergent diarrheaBEFORE the implementation of PDMAFTER the implementation of PDMPyrotinib+Trastuzumab+Docetaxel(N=106)Placebo+Trastuzumab+Docetaxel(N=106)Pyrotinib+Trastuzumab+Docetaxel(N=72)Placebo+Trastuzumab+Docetaxel(N=71)Diarrhea incidence, n (%)All grade106 (100.0)57 (53.8)72 (100.0)36 (50.7)Grade 112 (11.3)32 (30.2)7 (9.7)28 (39.4)Grade 241 (38.7)18 (17.0)39 (54.2)6 (8.5)Grade 353 (50.0)7 (6.6)26 (36.1)2 (2.8)Cycle 147 (44.3)4 (3.8)21 (29.2)2 (2.8)Cycle 222 (21.8)2 (1.9)7 (10.1)0Cycle 314 (14.1)05 (7.2)0Cycle 411 (11.1)2 (1.9)3 (4.5)0Grade 4 or 50000Median time to the first onset, days (IQR)All grade4 (2 to 5)7 (4 to 28)3 (2 to 4)6 (5 to 12)Grade 39 (5 to 11)16 (7 to 24)9 (6 to 12)11 (6 to 16)Median duration per diarrhea episode, days (IQR)All grade4 (2 to 9)2 (2 to 4)2 (1 to 5)2 (1 to 3)Grade 32 (2 to 3)2 (2 to 2)2 (1 to 2)1 (1 to 1)Median cumulative duration, days (IQR)Grade 36 (3 to 9)2 (2 to 3)2 (2 to 5)1 (1 to 1)Median time since the first onset to recovery, days (IQR)All grade7 (3 to 12)2 (2 to 4)3 (1 to 10)2 (1 to 4)Note: PDM, proactive diarrhea management; IQR, interquartile range. Citation Format: Benlong Yang, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Fei Wu, Shulin Liu, Xiang Lin, Jianjun Zou. Proactive diarrhea management improved tolerability of pyrotinib in combination with trastuzumab and docetaxel in patients with HER2+ early or locally advanced breast cancer: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-18-06.

APA, Harvard, Vancouver, ISO, and other styles

25

Ribbing Gren, Magnus. "The Qinghua “Jinteng” Manuscript: What it Does Not Tell Us about the Duke of Zhou." T’oung Pao 102, no. 4-5 (November 29, 2016): 291–320. http://dx.doi.org/10.1163/15685322-10245p01.

Full text

Abstract:

This study suggests that the so-called “Jinteng” manuscript held by Qinghua University should be read independently of its received counterpart. When read on its own terms, the manuscript provides a straightforward account of rituals surrounding the Duke of Zhou’s ascension to the throne after the demise of King Wu. As such it represents a continuation of King Wu’s abdication in favor of his meritorious brother, as recorded in the Yi Zhou shu. Read in this light, the fourth century BCE manuscript provides further evidence for the prominence of abdication doctrines during the Warring States period, an intellectual tradition that was deemed subversive in the early empire and became gradually obliterated over the course of the Qin-Han dynasties. Cet article propose de lire le manuscrit dit “Jinteng” conservé à l’université Qinghua indépendamment des textes reçus qui lui correspondent. Considéré par lui-même, le manuscrit offre une relation claire des rituels ayant entouré l’accession au trône du duc de Zhou après la mort du roi Wu. De ce fait, il représente le prolongement de l’abdication du roi Wu en faveur de son vertueux frère telle qu’elle est relatée dans le Yi Zhou shu. Considéré sous cet angle, ce manuscrit du IVe siècle avant notre ère offre de nouveaux arguments en faveur de l’importance des doctrines sur l’abdication à l’époque des Royaumes Combattants, alors que cette tradition intellectuelle était considérée comme subversive au début de l’empire et qu’elle est progressivement tombée dans l’oubli sous les Qin et les Han.

APA, Harvard, Vancouver, ISO, and other styles

26

안예선. "Pre-Han Wu Di Period in Han-Shu ― Compare with Shi-Ji." Journal of Chinese Language and Literature ll, no. 69 (June 2015): 201–28. http://dx.doi.org/10.26586/chls.2015..69.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Xiaofei Tian. "Remaking History: The Shu and Wu Perspectives in the Three Kingdoms Period." Journal of the American Oriental Society 136, no. 4 (2016): 705. http://dx.doi.org/10.7817/jameroriesoci.136.4.0705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shu, Yongqian, Yueyin Pan, Ping Lu, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, et al. "Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis." Cancer Research 83, no. 8_Supplement (April 14, 2023): CT076. http://dx.doi.org/10.1158/1538-7445.am2023-ct076.

Full text

Abstract:

Abstract Background: Tislelizumab, an anti-programmed cell death protein 1 (PD-1) antibody, + chemotherapy (chemo) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) vs placebo + chemo, with a manageable safety profile, as a first line (1L) treatment for patients (pts) with advanced or metastatic esophageal squamous cell carcinoma (ESCC) at interim analysis of the phase 3 RATIONALE-306 study. We report data from the China subgroup analysis. Methods: In this randomized, double-blind, global study, adults with unresectable locally advanced or metastatic ESCC, with no prior systemic treatment for advanced disease were enrolled regardless of programmed death-ligand 1 (PD-L1) expression status. Pts were randomized (1:1); stratified by region, prior definitive therapy, and investigator-chosen chemo (platinum + fluoropyrimidine or platinum + paclitaxel). Pts received tislelizumab (T) 200 mg intravenously + chemo (C) (Arm T+C) or placebo (P) + chemo (Arm P+C) once every three weeks; treatment continued until disease progression by investigator per RECIST v1.1, intolerable toxicity, or withdrawal. The primary endpoint was OS in the intent-to-treat (ITT) population. Secondary endpoints included investigator-assessed progression-free survival (PFS) per RECIST v1.1, objective response rate (ORR), and duration of response (DoR), in addition to safety. Results: Of 649 pts in the overall population, 370 (57.0%) were enrolled from China. At data cutoff (Feb 28, 2022), the median study follow-up in the China subgroup (ITT population) was 15.8 months (mo) in Arm T+C (n=182) and 10.6 mo in Arm P+C (n=188). Longer OS (median OS 16.6 mo vs 11.2 mo; unstratified hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.54, 0.89) and PFS (median PFS 8.3 mo vs 5.6 mo; unstratified HR 0.58, 95% CI 0.45, 0.75) indicate survival benefit in Arm T+C vs P+C, respectively. Arm T+C had higher response rates and more durable responses than Arm P+C; ORR was 64.8% vs 44.1% (odds ratio 2.33 [95% CI 1.53, 3.55]) respectively, and median DoR was 7.4 mo (95% CI 5.6, 9.5) vs 5.7 mo (95% CI 4.3, 7.5), respectively. Similar proportions of pts in Arm T+C vs P+C had ≥1 treatment-related adverse event (TRAE; 98.8% vs 98.9%) and ≥grade 3 TRAEs (72.9% vs 73.4%). Serious TRAEs occurred in 27.6% vs 21.2% of pts in Arm T+C vs P+C, and TRAEs leading to death occurred in 2.9% vs 1.6% of pts, respectively. Treatment-emergent adverse events leading to discontinuation occurred in 28.2% vs 17.4%, in Arm T+C vs P+C. Conclusions: In the China subgroup, 1L tislelizumab + chemo demonstrated clinically meaningful improvement in OS, PFS, ORR, and DoR vs placebo + chemo in pts with advanced or metastatic ESCC, with a manageable safety profile, consistent with published results in the overall population. Acknowledgments: This study was sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Emma Ashman, BSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd. Citation Format: Yongqian Shu, Yueyin Pan, Ping Lu, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Yi Ba, Zhiyong He, Yuxian Bai, Jianhua Chen, Guohua Yu, Yanyan Peng, Hongqian Wu, Lei Wang, Liyun Li, Jianming Xu. Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT076.

APA, Harvard, Vancouver, ISO, and other styles

29

Kang, Young Seok, and Yong Seok Ji. "Biomechanical Analysis of Ground Reaction Force on Jump Lotus Kick in Wu-shu." Journal of Sport and Leisure Studies 33 (August 31, 2008): 831–38. http://dx.doi.org/10.51979/kssls.2008.08.33.831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Kwon, Min Gyun. "The Disaster View of Pan-Ku seen in Han-Shu Wu-hsing Chih." CHUNGGUKSA YONGU (The Journal of Chinese Historical Researches) 125 (April 30, 2020): 63–89. http://dx.doi.org/10.24161/chr.125.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

김양순. "Forty Eight Vows in Wu-liang-shou-jing-lian-yi-shu-wen-zan." BUL GYO HAK YEONGU-Journal of Buddhist Studies 18, no. ll (December 2007): 295–318. http://dx.doi.org/10.21482/jbs.18..200712.295.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Donati, Silvano. "“Quadrature detection for self-mixing interferometry” by Junfeng Wu and Fengfeng Shu: comment." Optics Letters 43, no. 18 (September 4, 2018): 4320. http://dx.doi.org/10.1364/ol.43.004320.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sun (孫飛燕), Feiyan. "On the Nature of the Tsinghua Bamboo-Slip Manuscript Chi jiu zhi ji Tang zhi wu." Bamboo and Silk 4, no. 2 (September 1, 2021): 246–70. http://dx.doi.org/10.1163/24689246-00402011.

Full text

Abstract:

Abstract The nature of the Tsinghua bamboo-slip manuscript Chi jiu zhi ji Tang zhi wu is different from that of the Yi Yin shuo, which is recorded in the ‘Zhuzi lüe’ of the Han shu ‘Yiwen zhi’. This manuscript is also not a story fabricated by people in the Warring States period. It is possible that what is presented in this manuscript was a legend passed from generation to generation within Yi Yin’s lineage. Unlike Yin zhi and Yin gao, this manuscript does not belong to the Shangshu category.

APA, Harvard, Vancouver, ISO, and other styles

34

Chiromo, Humphrey, and Humphrey Chiromo. "Modified Metal Organic Frameworks Supported Ni Single Atom Catalyst for Enhanced Photocatalytic Hydrogen Evolution Reaction." ECS Meeting Abstracts MA2023-01, no. 17 (August 28, 2023): 2800. http://dx.doi.org/10.1149/ma2023-01172800mtgabs.

Full text

Abstract:

Abstract Downsizing metal nanoparticle catalysts to form single-atom catalysts (SACs) has proven to be one of the best ways to enhance the catalysts’ activity and selectivity1-2 due to their unique characteristics such as nearly 100% atom utilization and well-defined active sites.3 However, the broad application of SACs in catalytic reactions is limited by their poor stability as they possess high surface energy and thus tend to aggregate and form nanoclusters or nanoparticles.4 To address this challenge, various supports such as metal oxides, carbon materials, and porous materials are widely used to stabilize the SACs.5 Metal organic frameworks (MOFs), a class of porous crystalline materials, have proven to be an ideal candidate to support SACs owing to their high surface area, high porosity, and abundant potential anchoring sites.6 It has been shown that immobilizing SACs on MOFs, which forms MOF supported SACs, can integrate the unique properties of SACs and MOFs and led to remarkable catalytic activity, selectivity, and stability toward various catalytic reactions.6-8 Application of MOF supported SACs in photocatalysis, organic linkers of metal-organic frameworks act as photosensitive units,9 However most pristine metal-organic frameworks possesses poor light absorption properties due to wide band gap.9To enhance the light harvesting properties of the metal organic framework its organic linker is functionalized.10-11 In my poster presentation, I will present my work where post-synthetic modification of UiO-66-NH2 MOF linker with 3,4,9,10 perylene tetracarboxylic dianhydride (PDA) an organic molecule with broad absorption edge,12and immobilization of Ni single atom catalyst on the zirconium cluster of the MOF was done. This resulted in enhanced optical properties and charge separation efficiency which was proved by a combination of UV-visible spectroscopy (UV-Vis), photoelectrochemical techniques, and X-ray absorption spectroscopy (XAS). Observed photophysical effects posed by the modifications of the UiO-66-NH2 were evaluated by photocatalytic hydrogen generation. References Yan, J.; Kong, L.; Ji, Y.; White, J.; Li, Y.; Zhang, J.; An, P.; Liu, S.; Lee, S.-T.; Ma, T., Single atom tungsten doped ultrathin α-Ni (OH) 2 for enhanced electrocatalytic water oxidation. Nature communications 2019, 10 (1), 1-10. Jiao, L.; Jiang, H.-L., Metal-organic-framework-based single-atom catalysts for energy applications. Chem 2019, 5 (4), 786-804. Qiao, B.; Wang, A.; Yang, X.; Allard, L. F.; Jiang, Z.; Cui, Y.; Liu, J.; Li, J.; Zhang, T., Single-atom catalysis of CO oxidation using Pt1/FeO x. Nature chemistry 2011, 3 (8), 634-641. Xia, C.; Qiu, Y.; Xia, Y.; Zhu, P.; King, G.; Zhang, X.; Wu, Z.; Kim, J. Y.; Cullen, D. A.; Zheng, D., General synthesis of single-atom catalysts with high metal loading using graphene quantum dots. Nature chemistry 2021, 13 (9), 887-894. Wu, J.; Xiong, L.; Zhao, B.; Liu, M.; Huang, L., Densely populated single atom catalysts. Small Methods 2020, 4 (2), 1900540. Huang, H.; Shen, K.; Chen, F.; Li, Y., Metal–organic frameworks as a good platform for the fabrication of single-atom catalysts. ACS Catalysis 2020, 10 (12), 6579-6586. Qu, W.; Chen, C.; Tang, Z.; Wen, H.; Hu, L.; Xia, D.; Tian, S.; Zhao, H.; He, C.; Shu, D., Progress in metal-organic-framework-based single-atom catalysts for environmental remediation. Coordination Chemistry Reviews 2023, 474, 214855. Szilágyi, P.; Rogers, D.; Zaiser, I.; Callini, E.; Turner, S.; Borgschulte, A.; Züttel, A.; Geerlings, H.; Hirscher, M.; Dam, B., Functionalised metal–organic frameworks: a novel approach to stabilising single metal atoms. Journal of Materials Chemistry A 2017, 5 (30), 15559-15566. He, J.; Wang, J.; Chen, Y.; Zhang, J.; Duan, D.; Wang, Y.; Yan, Z., A dye-sensitized Pt@ UiO-66 (Zr) metal–organic framework for visible-light photocatalytic hydrogen production. Chemical communications 2014, 50 (53), 7063-7066. Elcheikh Mahmoud, M.; Audi, H.; Assoud, A.; Ghaddar, T. H.; Hmadeh, M., Metal–Organic Framework Photocatalyst Incorporating Bis(4′-(4-carboxyphenyl)-terpyridine)ruthenium(II) for Visible-Light-Driven Carbon Dioxide Reduction. Journal of the American Chemical Society 2019, 141 (17), 7115-7121. Hendrickx, K.; Joos, J. J.; De Vos, A.; Poelman, D.; Smet, P. F.; Van Speybroeck, V.; Van Der Voort, P.; Lejaeghere, K., Exploring lanthanide doping in UiO-66: a combined experimental and computational study of the electronic structure. Inorganic Chemistry 2018, 57 (9), 5463-5474. Yu, H.; Joo, P.; Lee, D.; Kim, B. S.; Oh, J. H., Photoinduced Charge‐Carrier Dynamics of Phototransistors Based on Perylene Diimide/Reduced Graphene Oxide Core/Shell p–n Junction Nanowires. Advanced Optical Materials 2015, 3 (2), 241-247.

APA, Harvard, Vancouver, ISO, and other styles

35

Li, Xin. "Ancient China’s Political Culture in the Classics —On the Base of “Three Appeals” in Western Classical Rhetoric." Studies in Linguistics and Literature 7, no. 4 (October 19, 2023): p125. http://dx.doi.org/10.22158/sll.v7n4p125.

Full text

Abstract:

“Zouyi” is a kind of official document written by court officials and submitted to the emperor in ancient China, which serves the purpose of persuading. Aristotle’s “three appeals”, which consist of ethos, pathos and logos, perform the rhetorical function of persuading. Based on this, some correlation between China’s classics and Western classic thought comes into view. This paper selects three representative Zouyi: “qian chu shi biao”, “zhi an ce” and “jian Tai Zong Shi si shu” and gives primary attention to analyzing the “three appeals” presented in the selected discourses. This analysis will gain a glimpse into the rich political and cultural codes hidden within ancient China’s memorials, the relationship between the emperor and his ministers/officials, and the deep patriotism of the ministers in ancient China.

APA, Harvard, Vancouver, ISO, and other styles

36

Karlsson, Jens, and Rebecka Eriksson. "Vilande drakens elegi." Tidskrift för litteraturvetenskap 42, no. 2-3 (January 1, 2012): 154–65. http://dx.doi.org/10.54797/tfl.v42i2-3.11698.

Full text

Abstract:

The Sleeping Dragon’s Elegy: An Example of Occasional Verse in The Romance of the Three Kingdoms This article examines one example of occasional verse in the classic Chinese novel The Romance of the Three Kingdoms (Sanguo yanyi 三国演义, Luo Guanzhong, 14th century), with a focus on the historical situation in which the poem is placed and the political implications ascribed to it. The Romance of the Three Kingdoms is a work of tremendous cultural impact. Its retelling of historical events during the late Han dynasty continues to shape the general understanding of this period, regardless of the narrative being widely accepted as fiction based on history. The poem discussed here is one example of fictional occasional verse that highlights the importance of the practice during the period in question as well as during the early Ming dynasty when the novel was written. The novel takes place during a time in Chinese history called the “Three Kingdoms” period when the Han dynasty was falling apart into smaller, independent states. The three states of Wei, Wu, and Shu, their internal struggles and the wars between them, form the centre of the narrative. Crucial to an appreciation of the poem is the Battle of Red Cliff, a naval confrontation that took place in the year 208 AD, when the allied forces of Sun Quan and Liu Bei managed to overcome the otherwise stronger enemy. The battle brought together Shu military strategist Zhuge Liang, the “author” of the poem according to the novel, and the poem’s subject – Wu commander-in-chief Zhou Yu. In 210, upon hearing about Zhou Yu’s early demise, Zhuge Liang decides to attend his funeral despite hostile sentiments among Wu generals. He presents the poem – an elegy retelling Zhou Yu’s life and accomplishments – to persuade the Wu generals of his innocence in the matter of Zhou Yu’s death.

APA, Harvard, Vancouver, ISO, and other styles

37

Wu, Shuqiong. "Review of Shu, Zhang & Zhang (2019): Cognitive Linguistics and the study of Chinese." Review of Cognitive Linguistics 18, no. 2 (December 4, 2020): 590–95. http://dx.doi.org/10.1075/rcl.00072.wu.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Pérez Gutiérrez, Mikel, and Carlos Gutiérrez García. "Estudio bibliométrico sobre las monografías de artes marciales publicadas en España (1906-2006)." Revista de Artes Marciales Asiáticas 3, no. 4 (July 19, 2012): 22. http://dx.doi.org/10.18002/rama.v3i4.387.

Full text

Abstract:

This paper examines the martial arts monographs published in Spain between 1906 and 2006 from a bibliometric point of view. Starting from Pérez and Gutiérrez’s previous bibliography (2008), the total number of published monographs following the criteria of subject, decade and the combination of both was analyzed. The results showed a total of 2.036 books (1.285 original editions) with a prevalence of Japanese and Chinese martial arts. A group of eight subjects exceeded a hundred volumes (karate, judo/jujutsu, taijiquan, wu-shu/kung fu, classics, qigong, philosophy, history and education, and aikido), with two patterns of bibliographic evolution appearing. The first, represented by Japanese martial arts considered as a group and martial arts focused on the utilitarian and/or sporting performance aspects (judo/jujutsu, karate and wu-shu/kung fu), developed increasingly until the 80’s when it followed a steady-state and/or drop. The second model, which characterises the Chinese martial arts group and martial arts mainly focused on healthy and/or spiritual aspects of training (taijiquan, qigong, aikido), has increased significantly from the 90’s until the present moment. The interpretation of these patterns and the evolution of the martial arts bibliographic production in Spain highlights some aspects such as the development of the Spanish society and sports practice, bibliographic production, reading habits, or the cultural influences of eastern countries on Spain.

APA, Harvard, Vancouver, ISO, and other styles

39

随机电磁涡旋光束的深聚焦特性. "Tight Focusing of Stochastic Electromagnetic Vortex Beams." ACTA PHOTONICA SINICA 40, no. 11 (2011): 1744–50. http://dx.doi.org/10.3788/gzxb20114011.1744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Schröder, Sven, Kathrin Beckmann, Giovanna Franconi, Gesa Meyer-Hamme, Thomas Friedemann, Henry Johannes Greten, Matthias Rostock, and Thomas Efferth. "Can Medical Herbs Stimulate Regeneration or Neuroprotection and Treat Neuropathic Pain in Chemotherapy-Induced Peripheral Neuropathy?" Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–18. http://dx.doi.org/10.1155/2013/423713.

Full text

Abstract:

Chemotherapy-induced neuropathy (CIPN) has a relevant impact on the quality of life of cancer patients. There are no curative conventional treatments, so further options have to be investigated. We conducted a systematic review in English and Chinese language databases to illuminate the role of medical herbs. 26 relevant studies on 5 single herbs, one extract, one receptor-agonist, and 8 combinations of herbs were identified focusing on the single herbsAcorus calamus rhizoma,Cannabis sativa fructus,Chamomilla matricaria,Ginkgo biloba,Salvia officinalis,Sweet bee venom,Fritillaria cirrhosae bulbus,and the herbal combinations Bu Yang Huan Wu, modified Bu Yang Huan Wu plus Liuwei Di Huang, modified Chai Hu Long Gu Mu Li Wan,Geranii herbaplusAconiti lateralis praeparata radix, Niu Che Sen Qi Wan (Goshajinkigan), Gui Zhi Jia Shu Fu Tang (Keishikajutsubuto), Huang Qi Wu Wu Tang (Ogikeishigomotsuto), and Shao Yao Gan Cao Tang(Shakuyakukanzoto). The knowledge of mechanism of action is still limited, the quality of clinical trials needs further improvement, and studies have not yielded enough evidence to establish a standard practice, but a lot of promising substances have been identified. While CIPN has multiple mechanisms of neuronal degeneration, a combination of herbs or substances might deal with multiple targets for the aim of neuroprotection or neuroregeneration in CIPN.

APA, Harvard, Vancouver, ISO, and other styles

41

Kano, Yoshio, Shinichiro Takaguchi, Tsutomu Nohno, Fukumi Hiragami, Kenji Kawamura, Michael K. Iwama, Kanji Miyamoto, and Manabu Takehara. "Chinese Medicine Induces Neurite Outgrowth in PC12 Mutant Cells Incapable of Differentiation." American Journal of Chinese Medicine 30, no. 02n03 (January 2002): 287–95. http://dx.doi.org/10.1142/s0192415x02000260.

Full text

Abstract:

During continuous culture of neural PC12 cells, we obtained a drug-hypersensitive PC12 mutant cell that showed high stimulation of neurite outgrowth by various drugs. When several Chinese medicines such as Shu-Jing-Huo-Xie-Tang and Wu-Ling-San were provided to these PC12 mutant cells, the frequency of nerve growth factor (NGF)-induced neurite outgrowth increased approximately 30-fold compared to NGF alone. Neurite outgrowth induced by NGF in PC12 cells is accompanied by sustained activation of mitogen-activated protein kinase (MAPK); however, these Chinese medicines did not induce MAPK activity. The findings thus indicate that certain Chinese medicines may induce neurite outgrowth by a novel mechanism which is distinct from the NGF-activated pathway in PC12 mutant cells.

APA, Harvard, Vancouver, ISO, and other styles

42

강현욱, 한동유, and Ji-Tae Kim. "Relationship among Participation Degree, Flow in Leisure Experience and Quality of Life of Wu-Shu Athletes." Journal of Korean Alliance of Martial Arts. 12, no. 1 (June 2010): 135–45. http://dx.doi.org/10.35277/kama.2010.12.1.135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Boltz, Judith Magee. "Notes on modern editions of the Taoist Canon." Bulletin of the School of Oriental and African Studies 56, no. 1 (February 1993): 87–95. http://dx.doi.org/10.1017/s0041977x00001683.

Full text

Abstract:

The three publishing houses of Wen-wu in Peking, Shanghai shu-tien, and Ku-chi in Tientsin joined forces to produce a new edition of the Taoist Canon. The Tao-tsang they published in 1988 is meant to be an improvement on the so-called Cheng-t'ung Tao-tsang printed in 1921–23 by the Han-fen lou branch of Shanghai Commercial Press. The latter takes as its foundation the copy of the Ming Canon from the archives of the Pai-yün Kuan (White Cloud Abbey) in Peking. The woodcut edition of the Ming Canon contains two components. The core collection appeared under the title Ta Ming Tao-tsang ching in the years 1444–45 of the Cheng-t'ung reign period. A small supplement entitled Hsü Tao-tsang ching was issued in 1607.

APA, Harvard, Vancouver, ISO, and other styles

44

Editorial, E. "Retraction: Shuang-Qing L, Jiang-Ying G, Qun D, Zhong-Jie H, Shu-Hong L. Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis. Arch biol sci. 2013;65(3):1223-31. DOI: 10.2298/ABS1303223L." Archives of Biological Sciences 67, no. 4 (2015): 1435. http://dx.doi.org/10.2298/abs150707082e.

Full text

Abstract:

This is a notice of retraction of the article: Anticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis, published in the Archives of Biological Sciences in 2013, Vol. 65, Issue 3. The Editor-in-Chief has been informed that this paper is a redundant publication of an earlier paper: Shuang-Qing L, Jian-Ying G, Jun D, Qun D, Zhong-Jie H, Hong-Yuan L, Shu-Hong L. Anticoagulant effect of Huisheng oral solution in a rat model of thrombosis. Indian J Pharmacol. 2013;45(4):359-64. DOI: 10.4103/0253-7613.115018. This claim is correct and almost the entire paper is a copy of the earlier one. After confirmation of this fact, the Editor-in-Chief of the Archives of Biological Sciences has decided to retract the paper immediately. Link to the retracted article <a href="http://dx.doi.org/10.2298/ABS1303223L">10.2298/ABS1303223L</a>

APA, Harvard, Vancouver, ISO, and other styles

45

KIM, YOUNG-SIK. "A Study on Description of A famous sword revealed in 『Wu-Yue Chunqiu』 and 『Yue Jue Shu』." JOURNAL OF CHINESE HUMANITIES 82 (December 31, 2022): 233–51. http://dx.doi.org/10.35955/jch.2022.12.82.233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Yi, Guo, and Martin Lu. "Guodian Bamboo Texts and Pre-Qin Intellectual Thoughts (Guo Dian Zhu Jian Yu Xian Qin Xue Shu Si Xiang)a." Journal of Chinese Philosophy 31, no. 2 (June 2004): 297–301. http://dx.doi.org/10.1111/j.0301-8121.2004.155_1.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lin, Shu (Sophie), Hongbin Liu, Rui Tan, Weipeng Zhang, Chengxi He, Yue Rong, Zhuo Huang, et al. "Abstract 2531: FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations." Cancer Research 83, no. 7_Supplement (April 4, 2023): 2531. http://dx.doi.org/10.1158/1538-7445.am2023-2531.

Full text

Abstract:

Abstract B-cell lymphoma 2 (BCL-2) is a member of the anti-apoptotic BCL-2 family and is dysregulated in B-cell malignancies, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), acute myeloid leukemia (AML) and Non-Hodgkin’s lymphoma. Venetoclax (VEN), also known as ABT-199, is the only BCL-2 inhibitor approved by FDA for treating CLL/SLL and AML. VEN is a BH3-mimetic drug competitively inhibits BCL-2 by binding to the hydrophobic groove and thereby displacing proapoptotic proteins and inducing apoptosis. Despite high effectiveness of the initial treatment, most patients treated with VEN eventually relapse or develop resistance. An important resistance mechanism is acquisition of BCL-2 G101V mutation, detected in about 50% of CLL patients 19-42 months after receiving VEN. Other resistance mutations identified clinically so far include D103, A113G, R129L, and V156D, etc. Overcoming VEN-resistant Bcl-2 mutations represent an unmet medical need. Here, we introduce a novel and selective second-generation oral BCL-2 inhibitor, FCN-683, with sub-nano or single nanomolar affinity to BCL-2 and VEN-resistant BCL-2 mutations including G101V, D103E/V/Y, F104L, A113G, R129L and V156D. FCN-683 showed much higher affinity to BCL-2 than BCL-xL, suggesting its good potential to avoid BCL-xL-linked thrombocytopenia. FCN-683 exhibited comparable or superior anti-proliferation activities compared with VEN in various BCL-2-addicted human B-cell lymphoma cells, including DOHH2 follicular lymphoma cells, Toledo diffuse large B-cell lymphoma cells, and RS4;11 acute lymphoblastic leukemia cells, while sparing BCL-xL-dependent cells. Of note, FCN-683 displayed potent anti-proliferative activities against a panel of genetically engineered RS4;11 cells ectopically expressing VEN-resistant BCL-2 mutants such as G101V, D103 or several other mutants above-mentioned, outperforming VEN. Correspondingly, FCN-683 significantly inhibited tumor growth in mice xenografts derived from human B-cell lymphomas harboring BCL-2 or various VEN-resistant BCL-2 mutations and its anti-tumor efficacy was much superior to VEN. In non-clinical studies, FCN-683 possessed excellent pharmacokinetic (PK) properties comparable to VEN. Preferable safety profiles of FCN-683 were shown with no potential hERG inhibitory effect and less drug-drug interaction potential, as evidenced by no inhibitory effect (IC50 >50 μM) on CYP2C9 enzyme compared with VEN (IC50 1.05 μM). Together, FCN-683 is highly potent, selective and highly efficacious against a variety of clinically relevant VEN-resistance BCL-2 mutations in vitro and in vivo and exhibits favorable PK and safety profiles, highlighting its therapeutic potential to become an effective therapeutic approach for VEN-naïve or -resistant BCL-2-addicted B-cell malignancies. Citation Format: Shu (Sophie) Lin, Hongbin Liu, Rui Tan, Weipeng Zhang, Chengxi He, Yue Rong, Zhuo Huang, Jinhua Yu, Yunling Wang, Yangli Qi, Xingdong Zhao, Lihua Jiang, Yanxin Liu, Xilei Wang, Zongyao Zou, Jing Sun, Yuwei Gao, Weibo Wang, Xiaohui Guan, Yifang Wu. FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2531.

APA, Harvard, Vancouver, ISO, and other styles

48

Shaughnessy, Edward L. "Of Trees, a Son, and Kingship: Recovering an Ancient Chinese Dream." Journal of Asian Studies 77, no. 3 (August 2018): 593–609. http://dx.doi.org/10.1017/s0021911818000517.

Full text

Abstract:

The first volume of the Tsinghua University Warring States bamboo-strip manuscripts contains a text with passages that match medieval quotations of a text referred to asCheng Wu 程寤orAwakening at Cheng, which in turn is said to be a lost chapter of theYi Zhou Shu 逸周書orLeftover Zhou Documents. The passages concern one of Chinese literature's earliest interpretations of a dream, and were quoted in medieval encyclopedias in their sections on dreams. This article discusses the significance of this discovery both for Chinese textual history and for the interpretation of this particular dream. In particular, it shows that trees seen in the dream predict the Zhou conquest of Shang, and the subsequent Shang acquiescence to Zhou rule. It also notes that this discovery simultaneously confirms the antiquity of this text, but also calls into question the dominant traditional interpretation of the dream.

APA, Harvard, Vancouver, ISO, and other styles

49

Su, Yu-chi. "The Russian Understanding of Manchu in the Second Half of the 19th Century: Focusing on Zakharov’s Complete Manchu-Russian Dictionary and the Contemporary Works." Vestnik of Saint Petersburg University. Asian and African Studies 14, no. 1 (2022): 4–12. http://dx.doi.org/10.21638/spbu13.2022.101.

Full text

Abstract:

Sinology and Manchu studies in Russia are famous for their traditions and their own path of development. Since the 18th century, members of the Russian Orthodox mission devoted themselves to sinology and Manchu studies, especially in the second half of the 19th century, when they carried out a large number of studies on the history of the Qing dynasty and the Manchu language that deserve our attention. This article analyzes entries related to Manchu in the Complete Manchu-Russian Dictionary by I. I. Zakharov. By comparing selected entries of the Complete Manchu-Russian Dictionary with two OTHER Manchu Dictionaries, namely Da Qing Quan Shu and Yuzhi Zengding Qingwen Jian , the article demonstrates how I. I. Zakharov defined the vocabulary and differences of interpretations in these dictionaries. By comparing entries with information from contemporary works, such as Works on Chinese Issues by Russian Missionaries in Beijing in the Mid-19 th Century and the travel note Travel to China , this article provides an image to understand how vocabulary reflects Russians’ understanding and perception of the Qing Dynasty and Manchu in the second half of the 19th century.

APA, Harvard, Vancouver, ISO, and other styles

50

He, Min, Benlong Yang, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, et al. "Abstract P5-18-10: Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study." Cancer Research 82, no. 4_Supplement (February 15, 2022): P5–18–10—P5–18–10. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-18-10.

Full text

Abstract:

Abstract Background: A dose relationship may exist for both antitumor activity and toxicity of docetaxel in breast cancer (BC) patients, while 86% grade 4 neutropenia and 12% febrile neutropenia (FN) were reported when pretreated advanced breast cancer (ABC) patients received 100 mg/m2 docetaxel monotherapy without hematopoietic support. PHEDRA was a randomized, double-blind, multicenter, phase 3 study comparing the efficacy and safety of adding pyrotinib to trastuzumab and docetaxel as neoadjuvant treatment in women with HER2+ early or locally ABC (ClinicalTrials.gov: NCT03588091). We conducted this exploratory analysis to evaluate the effectiveness of mecapegfilgrastim, a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), as primary prophylaxis for neoadjuvant chemotherapy-induced neutropenia in BC patients. Methods: Patients with HER2-positive early or locally ABC were randomly assigned (1:1) to pyrotinib arm receiving 4 neoadjuvant cycles of docetaxel (100 mg/m2 iv d1 q3w), trastuzumab (8 mg/kg iv, cycle 1 d1, then 6 mg/kg d1 q3w), and pyrotinib (400 mg po qd, d1-21, q3w) or placebo arm with placebo, trastuzumab and docetaxel. Per protocol, patients were required to receive a single, 6-mg fixed dose of mecapegfilgrastim on Day 2 of each cycle. Other G-CSF was permitted if mecapegfilgrastim was unavailable at the local center or patients occurred mecapegfilgrastim intolerance. The incidence of neutropenia, FN, time to first neutropenia onset, duration per neutropenia event and cumulative neutropenia duration during neoadjuvant treatment period; and the incidences of grade 3/4 neutropenia, FN and decreased WBC count in Cycle 1 to 4 (C1-4) were presented. The data cutoff date was April 30, 2021. Results: Between July 23, 2018 and January 8, 2021, 355 patients were randomized (pyrotinib arm, n=178; placebo arm, n=177). Among them, 291 (82.0%) patients received a single, 6-mg fixed dose of mecapegfilgrastim in Cycle 1 and 270 (76.1%) patients received mecapegfilgrastim in each of the 4 cycles. Grade 3/4 neutropenia was reported in 33 (18.5%) patients in the pyrotinib arm and 36 (20.3%) patients in the placebo arm. Five (2.8%) patients in the pyrotinib arm and 2 (1.1%) patients in the placebo arm developed FN (5 FN occurred in C1; 2 FN occurred in C2). Median duration of grade 3/4 neutropenia was 3 days in the pyrotinib group and 3 days in the placebo group. Median cumulative duration of grade 3/4 neutropenia was 4 days and 3 days in the pyrotinib group and the placebo group, respectively. Grade 3/4 neutropenia mainly occurred during the first cycle of treatment for both pyrotinib (13.5%) and placebo arm (15.8%), reduced in the second cycle (5.9% vs 4.0%) and thereafter (C3: 1.8% vs 3.4%; C4: 2.4% vs 1.7%). Similar trends were observed for grade 3/4 WBC count decreased in Cycle 1 to 4. No grade 4 infection occurred. Overview of neutropenia, FN and WBC count decreased was summarized in Table 1. Consistent findings were observed in 291 mecapegfilgrastim treated patients. Conclusion: The exploratory analysis demonstrated 6-mg fixed dose of mecapegfilgrastim was effective when administrated as primary prophylaxis for neoadjuvant chemotherapy-induced neutropenia, which could be considered as a new treatment option for its advantage of once-per-cycle dosing and convenient dose management. Table 1.Overview of neutropenia, febrile neutropenia and WBC count decrease during neoadjuvant treatment period.Docetaxel+Trastuzumab+Pyrotinib(N=178)Docetaxel+Trastuzumab+Placebo (N=177)All randomized patients(N=355)Neutropenia, n (%)Any grade57 (32.0)54 (30.5)111 (31.3)Grade 16 (3.4)5 (2.8)11 (3.1)Grade 218 (10.1)13 (7.3)31 (8.7)Grade 315 (8.4)20 (11.3)35 (9.9)Grade 418 (10.1)16 (9.0)34 (9.6)Median time to first onset (IQR), days7 (6-63)6 (6-49)7 (6-53)Median duration per grade 3 or higher neutropenia, days (range)3 (1-16)3 (2-12)3 (1-16)Median cumulative duration of grade 3 or higher neutropenia, days (range)4 (2-16)3 (2-14)3 (2-16)FN, n (%)5 (2.8)2 (1.1)7 (2.0)Grade 3 or higher neutropenia, n (%) *Cycle 124 (13.5)28 (15.8)52 (14.6)Cycle 210 (5.9)7 (4.0)17 (4.9)Cycle 33 (1.8)6 (3.4)9 (2.6)Cycle 44 (2.4)3 (1.7)7 (2.1)Grade 3 or higher FN, n (%) *Cycle 12 (1.1)2 (1.1)4 (1.1)Cycle 22 (1.2)02 (0.6)Cycle 3000Cycle 4000Grade 3 or higher WBC count decreased, n (%) *Cycle 120 (11.2)20 (11.3)40 (11.3)Cycle 28 (4.7)2 (1.1)10 (2.9)Cycle 32 (1.2)1 (0.6)3 (0.9)Cycle 44 (2.4)2 (1.1)6 (1.8)Note: IQR, interquartile range; FN, febrile neutropenia; WBC, white blood cell.*The denominator indicates number of patients with mecapegfilgrastim for prophylaxis use in this cycle. Citation Format: Min He, Benlong Yang, Jiong Wu, Zhenzhen Liu, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Zefei Jiang, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Shulin Liu, Ping Yan, Jianjun Zou. Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-18-10.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Jian shu(wu shu)'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles